PE20070845A1 - Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf) - Google Patents
Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf)Info
- Publication number
- PE20070845A1 PE20070845A1 PE2006001185A PE2006001185A PE20070845A1 PE 20070845 A1 PE20070845 A1 PE 20070845A1 PE 2006001185 A PE2006001185 A PE 2006001185A PE 2006001185 A PE2006001185 A PE 2006001185A PE 20070845 A1 PE20070845 A1 PE 20070845A1
- Authority
- PE
- Peru
- Prior art keywords
- crf
- pyrazolo
- alpha
- derivatives useful
- corticotropin release
- Prior art date
Links
- 102400000739 Corticotropin Human genes 0.000 title abstract 2
- 101800000414 Corticotropin Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title abstract 2
- 229960000258 corticotropin Drugs 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- -1 4-METHOXY-2-METHYL-PHENYL Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN POLIMORFO 2 DE [3-(4-METOXI-2-METIL-FENIL)-2,5-DIMETIL-PIRAZOLO[1,5-a]PIRIMIDIN-7-IL]-[(S)-1-(3-METIL[1,2,4]OXADIAZOL-5-IL)PROPIL]AMINA, CARACTERIZADA POR UN ESPECTRO DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE LOS PICOS EXPRESADOS EN VALORES DE 2-THETA: 10,415 +/- 0,15; 12,125 +/- 0,15; 19,457 +/- 0,15; 23,51 +/- 0,15 OBTENIDOS CON UN DIFRACTOMETRO USANDO RADIACION K ALFA DE COBRE Y TIENE UN TERMOGRAMA DE CALORIMETRIA DIFERENCIAL DE BARRIDO CON UN INICIO A APROXIMADAMENTE T=110,35. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO POLIMORFO ES ANTAGONISTA DEL FATOR DE LIBRACION DE CORTICOTROPINA (CRF) UTIL EN EL TRATAMIENTO DE LA DEPRESION O ANSIEDAD
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519957.5A GB0519957D0 (en) | 2005-09-30 | 2005-09-30 | Chemical compound |
| PCT/US2005/037576 WO2006044958A1 (en) | 2004-10-19 | 2005-10-19 | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070845A1 true PE20070845A1 (es) | 2007-08-25 |
Family
ID=35395069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001219A PE20060586A1 (es) | 2004-10-19 | 2005-10-17 | DERIVADOS DE PIRAZOLO [1,5-a]PIRIMIDINA COMO ANTAGONISTAS DEL RECEPTOR CRF |
| PE2006001185A PE20070845A1 (es) | 2005-09-30 | 2006-09-28 | Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001219A PE20060586A1 (es) | 2004-10-19 | 2005-10-17 | DERIVADOS DE PIRAZOLO [1,5-a]PIRIMIDINA COMO ANTAGONISTAS DEL RECEPTOR CRF |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7879862B2 (es) |
| EP (2) | EP1802627B1 (es) |
| JP (2) | JP4901744B2 (es) |
| KR (2) | KR20070088621A (es) |
| CN (1) | CN101273043B (es) |
| AR (2) | AR051461A1 (es) |
| AU (2) | AU2005295353B2 (es) |
| BR (1) | BRPI0616767A2 (es) |
| CA (2) | CA2584567C (es) |
| CR (1) | CR9918A (es) |
| EA (1) | EA200801000A1 (es) |
| GB (1) | GB0519957D0 (es) |
| IL (1) | IL190225A0 (es) |
| MA (1) | MA29850B1 (es) |
| NO (2) | NO20072541L (es) |
| NZ (1) | NZ554082A (es) |
| PE (2) | PE20060586A1 (es) |
| RU (1) | RU2007118683A (es) |
| TW (2) | TW200626599A (es) |
| UA (1) | UA92756C2 (es) |
| WO (2) | WO2006044958A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1938309B (zh) * | 2003-12-22 | 2011-11-09 | 史密斯克莱.比奇曼（科克）有限公司 | Crf受体拮抗剂及其相关方法 |
| GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2709710A1 (en) | 2007-12-19 | 2009-07-09 | Vertex Pharmaceuticals Incorporated | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors |
| MY152687A (en) * | 2008-04-15 | 2014-10-31 | Eisai R&D Man Co Ltd | 3-phenylpyrazolo[5,1-b]thiazole compound |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| JPWO2011043387A1 (ja) * | 2009-10-08 | 2013-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
| US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102753527B (zh) * | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| WO2013074641A1 (en) | 2011-11-16 | 2013-05-23 | Array Biopharma Inc. | Piperidinyl- substituted cyclic ureas as gpr119 modulators |
| JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| HUE068315T2 (hu) | 2014-01-21 | 2024-12-28 | Neurocrine Biosciences Inc | CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére |
| RU2689788C2 (ru) * | 2014-01-22 | 2019-05-29 | Куровир Аб | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ |
| EP3582783B1 (en) | 2017-02-17 | 2023-06-07 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| SG11202105930QA (en) | 2018-12-07 | 2021-07-29 | Neurocrine Biosciences Inc | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| CN114502162B (zh) | 2019-09-27 | 2025-03-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
| JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
| KR20240016950A (ko) | 2021-05-04 | 2024-02-06 | 테나야 테라퓨틱스, 인코포레이티드 | 대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| EP0714898B1 (en) | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| US6664261B2 (en) | 1996-02-07 | 2003-12-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as CRF receptor antagonists |
| ES2168237T3 (es) | 1996-02-07 | 2007-04-01 | Neurocrine Biosciences, Inc. | Pirazolopirimidinas como antagonistas de receptores de crf. |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| PT915880E (pt) | 1996-07-24 | 2007-12-31 | Bristol Myers Squibb Pharma Co | Azol triazinas e pirimidinas |
| CA2259583C (en) * | 1996-07-24 | 2009-11-17 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
| JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| ATE301657T1 (de) * | 1998-01-28 | 2005-08-15 | Bristol Myers Squibb Pharma Co | Azolo-pyrimidine |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| CA2359041A1 (en) | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Co., Ltd. | Fat accumulation inhibitory agents |
| WO2000059908A2 (en) * | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| CA2379633C (en) * | 1999-09-30 | 2006-06-20 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| PL354675A1 (en) | 1999-09-30 | 2004-02-09 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| MXPA03009938A (es) * | 2001-04-30 | 2005-09-07 | Glaxo Group Ltd | Pirimidinas fusionadas como antagonistas del factor liberador de corticotropina. |
| EP1395591B1 (en) * | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| GB0117396D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| EP1511751B1 (en) | 2002-06-04 | 2008-03-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents |
| ES2285409T3 (es) * | 2003-01-16 | 2007-11-16 | Sb Pharmco Puerto Rico Inc | Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf. |
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| US20070021429A1 (en) * | 2003-04-09 | 2007-01-25 | Yves St-Denis | Condensed n-heterocyclic compounds and their use as crf receptor antagonists |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US20070293511A1 (en) * | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
| CN1938309B (zh) | 2003-12-22 | 2011-11-09 | 史密斯克莱.比奇曼（科克）有限公司 | Crf受体拮抗剂及其相关方法 |
| DE102004008807A1 (de) * | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| JP2008517060A (ja) * | 2004-10-19 | 2008-05-22 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびその製法 |
| US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
-
2005
- 2005-09-30 GB GBGB0519957.5A patent/GB0519957D0/en not_active Ceased
- 2005-10-17 AR ARP050104337A patent/AR051461A1/es not_active Application Discontinuation
- 2005-10-17 PE PE2005001219A patent/PE20060586A1/es not_active Application Discontinuation
- 2005-10-17 TW TW094136095A patent/TW200626599A/zh unknown
- 2005-10-19 EP EP05818308A patent/EP1802627B1/en not_active Expired - Lifetime
- 2005-10-19 RU RU2007118683/04A patent/RU2007118683A/ru not_active Application Discontinuation
- 2005-10-19 JP JP2007537996A patent/JP4901744B2/ja not_active Expired - Lifetime
- 2005-10-19 AU AU2005295353A patent/AU2005295353B2/en not_active Ceased
- 2005-10-19 CA CA2584567A patent/CA2584567C/en not_active Expired - Fee Related
- 2005-10-19 WO PCT/US2005/037576 patent/WO2006044958A1/en not_active Ceased
- 2005-10-19 KR KR1020077008794A patent/KR20070088621A/ko not_active Ceased
- 2005-10-19 US US11/576,957 patent/US7879862B2/en active Active
- 2005-10-19 NZ NZ554082A patent/NZ554082A/en not_active IP Right Cessation
-
2006
- 2006-09-28 TW TW095135886A patent/TW200745121A/zh unknown
- 2006-09-28 AR ARP060104269A patent/AR056104A1/es not_active Application Discontinuation
- 2006-09-28 AU AU2006298995A patent/AU2006298995B2/en not_active Ceased
- 2006-09-28 CA CA002624699A patent/CA2624699A1/en not_active Abandoned
- 2006-09-28 EP EP06805979A patent/EP1934222B1/en active Active
- 2006-09-28 WO PCT/EP2006/009531 patent/WO2007039264A1/en not_active Ceased
- 2006-09-28 PE PE2006001185A patent/PE20070845A1/es not_active Application Discontinuation
- 2006-09-28 EA EA200801000A patent/EA200801000A1/ru unknown
- 2006-09-28 JP JP2008532687A patent/JP2009510004A/ja not_active Ceased
- 2006-09-28 KR KR1020087007620A patent/KR20080063760A/ko not_active Withdrawn
- 2006-09-28 UA UAA200803939A patent/UA92756C2/ru unknown
- 2006-09-28 CN CN2006800355977A patent/CN101273043B/zh not_active Expired - Fee Related
- 2006-09-28 BR BRPI0616767-5A patent/BRPI0616767A2/pt not_active IP Right Cessation
-
2007
- 2007-05-16 NO NO20072541A patent/NO20072541L/no not_active Application Discontinuation
-
2008
- 2008-03-17 IL IL190225A patent/IL190225A0/en unknown
- 2008-04-04 MA MA30813A patent/MA29850B1/fr unknown
- 2008-04-23 NO NO20081941A patent/NO20081941L/no not_active Application Discontinuation
- 2008-04-23 CR CR9918A patent/CR9918A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070845A1 (es) | Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf) | |
| PE20081377A1 (es) | Compuestos de tiazol pirazolopirimidina | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| CR9219A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| PE20120814A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| EA200702044A1 (ru) | Имидазопиридазиновые соединения | |
| MY152888A (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists. | |
| ECSP088989A (es) | (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3 | |
| ECSP11011181A (es) | Compuestos orgánicos | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| PE20081159A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
| CO6400144A2 (es) | Derivados aminoéster de alcaloides y composición medicinal de los mismos | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR072431A1 (es) | Procedimiento mejorado para la preparacion de 2-trifluormetil-5-(1-substituido)alquilpiridina | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| SV2005002061A (es) | Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538 | |
| PE20160604A1 (es) | Derivados de etinilo como antagonistas del receptor metabotropico de glutamato | |
| EA200800264A1 (ru) | Производные пиразоло[3,4-d]азепина как антагонисты н3-рецепторов гистамина | |
| UY31338A1 (es) | Compuestos novedosos activos como antagonistas de receptores muscarinicos | |
| SV2006002089A (es) | Nuevos imidazoles ref. docket 18699 (pc26195a) | |
| PE20071159A1 (es) | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |